Compare Analog Devices, Inc. (ADI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Novavax Inc — how do they compare? Analog Devices, Inc. trades at $384 (market cap $187.67B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Analog Devices, Inc. is far larger — about 143.3× Novavax Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ADI | NVAX | |
|---|---|---|
Market Cap | $187.67B | $1.31B |
Sector | Technology | Health |
52-Week High | $445.48 | $11.19 |
52-Week Low | $225.20 | $6.22 |
Enterprise Value | $192.92B | $889.30M |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.98, up 0.27% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $472.29 highlight positive momentum. The company maintains robust profitability with a 26.01% net income margin and a dividend payout of $1.10, supported by solid cash flow from operations of $4.81 billion in 2025.
Outlook remains favorable with projected revenue growth to $12.7 billion in 2026, though elevated valuation ratios and competitive pressures in semiconductors pose risks. Institutional buying and a lack of sell ratings underscore confidence, but investors should monitor debt levels and market volatility.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
